• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肠道微生物群与临床疾病：肥胖症和非酒精性脂肪性肝病

Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease.

作者信息

Park Ji Sook, Seo Ji Hyun, Youn Hee-Shang

机构信息

Department of Pediatrics, Gyeongsang National University School of Medicine, Jinju, Korea.

出版信息

Pediatr Gastroenterol Hepatol Nutr. 2013 Mar;16(1):22-7. doi: 10.5223/pghn.2013.16.1.22. Epub 2013 Mar 31.

DOI:10.5223/pghn.2013.16.1.22
PMID:24010102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3746040/
Abstract

The prevalence of obesity is increasing worldwide. Obesity can cause hyperlipidemia, hypertension, cardiovascular diseases, metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). Many environmental or genetic factors have been suggested to contribute to the development of obesity, but there is no satisfactory explanation for its increased prevalence. This review discusses the latest updates on the role of the gut microbiota in obesity and NAFLD.

摘要

全球肥胖症的患病率正在上升。肥胖会导致高脂血症、高血压、心血管疾病、代谢综合征和非酒精性脂肪性肝病（NAFLD）。许多环境或遗传因素被认为与肥胖症的发生有关，但对于其患病率上升却没有令人满意的解释。本综述讨论了肠道微生物群在肥胖症和非酒精性脂肪性肝病中作用的最新进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c82a/3746040/3ba9cb6eba15/pghn-16-22-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c82a/3746040/3ba9cb6eba15/pghn-16-22-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c82a/3746040/3ba9cb6eba15/pghn-16-22-g001.jpg

相似文献

1
Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease.肠道微生物群与临床疾病：肥胖症和非酒精性脂肪性肝病
Pediatr Gastroenterol Hepatol Nutr. 2013 Mar;16(1):22-7. doi: 10.5223/pghn.2013.16.1.22. Epub 2013 Mar 31.
2
Obesity, fatty liver disease and intestinal microbiota.肥胖、脂肪肝疾病与肠道微生物群
World J Gastroenterol. 2014 Nov 28;20(44):16452-63. doi: 10.3748/wjg.v20.i44.16452.
3
The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms.肠道微生物群在非酒精性脂肪性肝病中的作用：作用机制途径
Biosci Microbiota Food Health. 2019;38(3):81-88. doi: 10.12938/bmfh.18-032. Epub 2019 May 8.
4
The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.肠道微生物群在非酒精性脂肪性肝病和心血管疾病发生发展中的代谢作用
Int J Mol Sci. 2016 Jul 29;17(8):1225. doi: 10.3390/ijms17081225.
5
Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.肠道微生物群对非酒精性脂肪性肝病的贡献：机制途径。
Clin Nutr ESPEN. 2021 Aug;44:61-68. doi: 10.1016/j.clnesp.2021.05.012. Epub 2021 May 25.
6
Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.肠道微生物群在非酒精性脂肪性肝病中的作用
Nutr Clin Pract. 2015 Dec;30(6):780-6. doi: 10.1177/0884533615605811. Epub 2015 Oct 8.
7
Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.肠道微生物群与非酒精性脂肪性肝病：发病机制、微生物群特征及治疗干预
Microorganisms. 2021 Apr 29;9(5):957. doi: 10.3390/microorganisms9050957.
8
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.槲皮素对高脂饮食诱导的小鼠非酒精性脂肪性肝病的保护作用是通过调节肠道微生物群失衡和相关肠-肝轴激活来介导的。
Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25.
9
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群：非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
10
Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.肠道微生物群移植、槲皮素与高脂饮食之间的功能相互作用决定无菌小鼠非酒精性脂肪性肝病的发生。
Mol Nutr Food Res. 2019 Apr;63(8):e1800930. doi: 10.1002/mnfr.201800930. Epub 2019 Feb 4.

引用本文的文献

1
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).非酒精性脂肪性肝病 (NAFLD) 的治疗进展。
Front Endocrinol (Lausanne). 2023 Jan 16;13:1087260. doi: 10.3389/fendo.2022.1087260. eCollection 2022.
2
Dietary betaine and/or TMAO affect hepatic lipid accumulation and glycometabolism of Megalobrama amblycephala exposed to a high-carbohydrate diet.饲粮甜菜碱和/或 TMAO 影响高脂肪糖饲料暴露下团头鲂肝脏脂类积累和糖代谢。
Fish Physiol Biochem. 2024 Feb;50(1):59-75. doi: 10.1007/s10695-022-01160-7. Epub 2022 Dec 29.
3
Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment.

本文引用的文献

1
The function of our microbiota: who is out there and what do they do?我们的微生物组的功能：它们是谁，它们在做什么？
Front Cell Infect Microbiol. 2012 Aug 9;2:104. doi: 10.3389/fcimb.2012.00104. eCollection 2012.
2
Gut microbiota and obesity.肠道微生物群与肥胖。
Dig Dis. 2012;30(2):196-200. doi: 10.1159/000336965. Epub 2012 Jun 20.
3
Gut microbiota and nonalcoholic fatty liver disease.肠道微生物群与非酒精性脂肪性肝病。
非酒精性脂肪性肝病的分子特征及治疗的最新研究进展。
Front Endocrinol (Lausanne). 2022 Nov 29;13:1002916. doi: 10.3389/fendo.2022.1002916. eCollection 2022.
4
The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis.益生菌/益生元/合生菌在非酒精性脂肪性肝病患者能量代谢生物标志物中的潜在作用：系统评价和荟萃分析。
Front Public Health. 2022 Jul 25;10:862266. doi: 10.3389/fpubh.2022.862266. eCollection 2022.
5
Liver metabolomics identifies bile acid profile changes at early stages of alcoholic liver disease in mice.肝脏代谢组学在小鼠酒精性肝病早期识别胆汁酸谱的变化。
Chem Biol Interact. 2022 Jun 1;360:109931. doi: 10.1016/j.cbi.2022.109931. Epub 2022 Apr 14.
6
Current treatment paradigms and emerging therapies for NAFLD/NASH.NAFLD/NASH 的现行治疗模式和新兴疗法。
Front Biosci (Landmark Ed). 2021 Jan 1;26(2):206-237. doi: 10.2741/4892.
7
The Potential Mediation of the Effects of Physical Activity on Cognitive Function by the Gut Microbiome.肠道微生物群对体育活动对认知功能影响的潜在介导作用。
Geriatrics (Basel). 2020 Sep 25;5(4):63. doi: 10.3390/geriatrics5040063.
8
Role and effective therapeutic target of gut microbiota in NAFLD/NASH.肠道微生物群在非酒精性脂肪性肝病/非酒精性脂肪性肝炎中的作用及有效治疗靶点
Exp Ther Med. 2019 Sep;18(3):1935-1944. doi: 10.3892/etm.2019.7781. Epub 2019 Jul 17.
9
Gut microbiota: a new path to treat obesity.肠道微生物群：治疗肥胖的新途径。
Int J Obes Suppl. 2019 Apr;9(1):10-19. doi: 10.1038/s41367-019-0011-7. Epub 2019 Apr 12.
10
Nonalcoholic fatty liver disease in obese and nonobese pediatric patients.肥胖和非肥胖儿科患者的非酒精性脂肪性肝病
Korean J Pediatr. 2019 Jan;62(1):30-35. doi: 10.3345/kjp.2018.06786. Epub 2018 Sep 17.
Ann Hepatol. 2012 Jul-Aug;11(4):440-9.
4
The microbiota of the gut in preschool children with normal and excessive body weight.学龄前儿童正常体重和超重人群的肠道微生物群。
Obesity (Silver Spring). 2012 Nov;20(11):2257-61. doi: 10.1038/oby.2012.110. Epub 2012 May 1.
5
The impact of the gut microbiota on human health: an integrative view.肠道微生物群对人类健康的影响：综合观点。
Cell. 2012 Mar 16;148(6):1258-70. doi: 10.1016/j.cell.2012.01.035.
6
Intestinal microbiota and overweight.肠道微生物群与超重。
Benef Microbes. 2010 Nov;1(4):407-21. doi: 10.3920/BM2010.0030.
7
Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.肠道微生物群、肠道通透性、肥胖引起的炎症和肝损伤。
JPEN J Parenter Enteral Nutr. 2011 Sep;35(5 Suppl):14S-20S. doi: 10.1177/0148607111413772. Epub 2011 Aug 1.
8
Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease?肥胖与肠道微生物群：促进结肠发酵能否预防肥胖和代谢性疾病？
Genes Nutr. 2011 Aug;6(3):241-60. doi: 10.1007/s12263-011-0230-1. Epub 2011 May 11.
9
Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms.益生菌作为一种新兴的治疗非酒精性脂肪性肝病（NAFLD）的治疗策略：聚焦分子和生化机制。
J Nutr Biochem. 2011 Aug;22(8):699-711. doi: 10.1016/j.jnutbio.2010.10.002. Epub 2011 Feb 2.
10
Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age.10 岁时，正常体重儿童与超重儿童的初始饮食和微生物环境存在差异。
J Pediatr Gastroenterol Nutr. 2011 Jan;52(1):90-5. doi: 10.1097/MPG.0b013e3181f3457f.